In animal studies, the LGMN inhibitor RR-11a was found to improve myocardial remodeling and reduce the rate of cardiac rupture by inhibiting ECM degradation, demonstrating that LGMN may be a therapeutic target for myocardial infarction. The gene discussed is LGMN; the disease is myocardial infarction.